A5038497836- Acute Myeloid Leukemia Research
- Advanced Breast Cancer Therapies
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Colorectal Cancer Surgical Treatments
- Health disparities and outcomes
- Global Health Care Issues
- HER2/EGFR in Cancer Research
- Employment and Welfare Studies
- Protein Degradation and Inhibitors
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Infant Development and Preterm Care
- Histone Deacetylase Inhibitors Research
- Cancer-related Molecular Pathways
- Electronic Health Records Systems
- Data Quality and Management
- Medical Coding and Health Information
- Ethics in Clinical Research
- Vascular Tumors and Angiosarcomas
- Advanced Radiotherapy Techniques
- Radiomics and Machine Learning in Medical Imaging
- Multiple Myeloma Research and Treatments
- Lung Cancer Research Studies
- Advances in Oncology and Radiotherapy
Cardiff University
2022-2024
Institute of Cancer Research
2015-2019
PURPOSE CDK4/6 inhibitors are used to treat estrogen receptor (ER)–positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of palbociclib plus letrozole as neoadjuvant PATIENTS AND METHODS Postmenopausal women ER-positive primary BC and tumors greater than or equal 2.0 cm were randomly assigned 3:2:2:2 (2.5 mg/d) for 14 weeks (A); 2 weeks, then (B); (C); weeks. Palbociclib 125 mg/d was administered orally...
To determine the optimal induction chemotherapy regimen for younger adults with newly diagnosed AML without known adverse risk cytogenetics.
Liposomal daunorubicin and cytarabine (CPX-351) improved overall survival (OS) compared with 7+3 chemotherapy in older patients secondary acute myeloid leukemia (AML); to date, there have been no randomized studies younger patients. The high-risk cohort of the UK NCRI AML19 trial (ISRCTN78449203) CPX-351 FLAG-Ida adults newly diagnosed adverse cytogenetic AML or myelodysplastic syndromes (MDS). A total 189 were (median age, 56 years). Per clinical criteria, 49% had de novo AML, 20% 30% MDS....
Abstract Aim Health Technology Wales sought to evaluate the clinical and cost‐effectiveness of contact X‐ray brachytherapy (CXB) for early‐stage rectal cancer. Methods Relevant studies were identified through systematic searches MEDLINE, Embase, Cochrane Library Scopus. A cost‐utility model was developed estimate CXB in National Service Wales, using results Organ Preservation Early Rectal Adenocarcinoma (OPERA) trial. Patient perspectives obtained Papillon Support group All‐Wales Cancer...
Background: Following the RATIFY study Midostaurin in combination with "7 + 3" like chemotherapy has become standard of care for patients newly diagnosed FLT3 mutated AML. The ALFA 0701 trial also suggested a benefit Gemtuzumab Ozogamicin (GO) AML however GO-based induction not been formally assessed. Aims: To assess safety midostaurin and intensive therapy to impact on MRD kinetics Methods: NCRI AML19 randomised receive DA 3 10 (Daunorubicin 60mg/m2 days 1,3,5 plus AraC 100mg/m2 bd 1-10)...
Breast cancer is a diverse and varied disease. Recent research has shown that the collection of multiple biopsies before surgery can help researchers determine how responding to treatment predict for long-term outcomes. However be uncomfortable, sometimes clinicians teams in hospitals may reluctant offer clinical trials requiring several patients who have been recently diagnosed with breast cancer. The Institute Cancer Research Clinical Trials Statistics Unit (ICR-CTSU) oversees large number...
Background ICR-CTSU introduced EDC in 2012; this necessitated a revision of the systems and processes implemented for paper CRFs. Traditionally sites manually completed, signed posted CRFs to ICR-CTSU. Once received, were tracked transcribed onto study database by member trial team. Databases contained multiple complex validations aid central data management. Data queries raised sent post. These had be revised when was alteration CRF design integral this.
e15622 Background: Health Technology Wales sought to evaluate the clinical and cost-effectiveness of contact x-ray brachytherapy (CXB) in conjunction with external-beam radiotherapy (EBRT), compared EBRT alone for early-stage (T2–3b, N0–1, M0) rectal cancer a surgically fit population. Methods: An economic analysis was performed using decision analytical, state transition model. Analysis from third-party payer perspective over life-time horizon. The model populated data Organ Preservation...
Abstract Background This review aimed to quantify the impact of allied health professionals (AHPs) embedded in neonatal services on outcomes by asking following questions: Q1. What is effectiveness with compared without professionals? Q2. early interventions provided units? Research Implications and Evidence Gaps There was very little directly relevant evidence AHPs services. Most related multidisciplinary team working or AHPs. Few intervention trials were from UK, leading uncertainty about...
Introduction Artificial intelligence (AI) technologies are becoming more widespread in daily life, including health and care settings. AI is being developed for use many areas, diagnostics, treatment planning, patient monitoring. There new challenges additional considerations when performing a technology assessment (HTA) healthcare. Methods Health Technology Wales has guidance checklist of researchers to undertaking an HTA on AI. These documents were created as result involvement discussions...
Background: The NCRI AML17 trial established the prognostic impact of measurable residual disease (MRD) by RT-qPCR in patients with NPM1mut AML. Patients testing MRD+ve peripheral blood (PB) following second course chemotherapy (PC2) had a high risk relapse (77% at 3 years) and poor overall survival (OS, 25% years). subsequent AML19 randomised 1033 newly diagnosed AML or MDS-EB2 between FLAG-Ida DA3 + 10 either single dose GO (GO1) fractionated schedule (GO2). No FLT3 inhibition was used....
Background: Following the RATIFY study, Midostaurin in combination with "7 + 3" like chemotherapy became standard of care for patients newly diagnosed FLT3 mutated (mut) AML. The ALFA 0701 trial suggested a benefit Gemtuzumab Ozogamicin (GO) FLT3mut AML that was also apparent meta-analysis GO induction (Hills et al. JCO, 2014,15(9):986. GO-based has not been formally assessed respect to safety, response and survival Aims: To assess safety efficacy (in single or fractionated dose) given...
570 Background: PALLET randomized 307 postmenopausal women with ER+ primary breast cancer to one of 4 treatment groups (3:2:2:2 ratio): A: L for 14wks; B: 2wks then L+P C: P D: 14wks. This allowed a 1:2 comparison (Group A) vs (Groups B+C+D) at was given 125mg/d PO (21 days on, 7 off). Adding markedly enhanced Ki67 suppression and Complete Cell Cycle Arrest (CCCA, < 2.7%) by 14wks but did not substantially increase clinical response. We now report exploratory analysis the association...